MedPath

Real-World Data Supports Efficacy of Opdivo Plus Yervoy in mRCC Treatment

A recent study highlights the real-world effectiveness of Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with intermediate- or poor-risk advanced metastatic renal cell carcinoma (mRCC), showing promising overall survival and progression-free survival rates.

Among patients with intermediate- or poor-risk advanced metastatic renal cell carcinoma (mRCC), new trial data further supports the understanding of the real-world utilization and long-term effectiveness of first line Opdivo (nivolumab) plus Yervoy (ipilimumab), according to study findings published in JCO Clinical Cancer Informatics.
In a retrospective analysis, after a median follow-up of 22.4 months, the median overall survival (OS) and real-world progression-free survival (rwPFS) were 38.4 months and 11.1 months, respectively. In total, 89 patients died, and 120 patients died or developed progressive disease during the study period.
Treatment-related side effects were experienced by 89 (47.6%) patients, which included fatigue (13.4%), rash (10.2%), diarrhea (7%), nausea (6.4%) and colitis (3.7%). Common reasons for the discontinuation of treatment included progressive disease (25.1%), toxicity (21.4%), completed planned treatment (11.8%), hospice (4.8%) and death (4.8%).
Factors that were significantly associated with both OS and rwPFS included an Eastern Cooperative Oncology Group performance status score of 2 or more, stage 4 disease at initial diagnosis and The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model poor-risk group.
Out of 187 patients (mean age, 63 years) identified in the analysis, 60.4% had an intermediate IMDC prognostic risk, 74 (39.6%) patients had poor risk, 37 (19.8%) patients had an Eastern Cooperative Oncology Group performance status score of 2 or more and 61% had a score of 0 to 1. Patients receiving second line therapy (86 patients) received Cometriq (cabozantinib) (54.7%) and Votrient (pazopanib) (10.5%).
The most common sites of metastasis were the lung (57.8%), bone (31.6%) and lymph nodes (30.5%). Forty-six percent of patients had metastases in two or more sites. Metastases were also observed in the liver (17.6%) and brain (6.4%).
“In conclusion, this real-world study supports the clinical effectiveness of first-line [Opdivo plus Yervoy] combination therapy for patients with IMDC [intermediate- or poor-risk] mRCC in the community oncology setting,” study authors concluded.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reference News

[1]
Real-World Data May Support Opdivo Plus Yervoy Efficacy ...
curetoday.com · Jan 9, 2025

Study supports Opdivo plus Yervoy's effectiveness for intermediate- or poor-risk mRCC, showing median OS of 38.4 months ...

© Copyright 2025. All Rights Reserved by MedPath